Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Public ClinicalTrials.gov record NCT01652092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT01652092
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Enrollment
- 57 participants
Conditions and interventions
Conditions
- Bare Lymphocyte Syndrome
- CD40 Ligand Deficiency
- Chediak-Higashi Syndrome
- Chronic Granulomatous Disease
- Common Variable Immunodeficiency
- Griscelli Syndrome
- Hemophagocytic Lymphohistiocytosis
- Hyper IgM Syndrome
- Langerhan's Cell Histiocytosis
- Omenn's Syndrome
- Reticular Dysgenesis
- SCID
- Wiskott-Aldrich Syndrome
- X-linked Lymphoproliferative Disease
Interventions
- Alemtuzumab 0.2 mg Drug
- Alemtuzumab 0.3 mg Drug
- Busulfan Drug
- Cyclophosphamide Drug
- Fludarabine phosphate 30 mg Drug
- Fludarabine phosphate 40 mg Drug
- MESNA Drug
- Melphalan Drug
- Stem Cell Transplantation Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- Up to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 3, 2012
- Primary completion
- Dec 29, 2025
- Completion
- Nov 30, 2026
- Last update posted
- Jan 14, 2026
2012 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01652092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01652092 live on ClinicalTrials.gov.